OXA(17-33) 是一种高效、选择性的 orexin-1 receptor (OX1) 激动剂。OXA(17-33) 对 OX1 (EC50=8.29 nM) 的选择性比 OX2 (187 nM) 高 23 倍。 OXA(17-33) 是一种具有高效能与 ...

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, “Over ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. The Big ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TheraCryf plc has been awarded a European patent for its highly selective Orexin 1 receptor antagonist ...

NLS Pharmaceutics (NLSP) shared preclinical data demonstrating the potential of its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to ...

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024. An imbalance in Orexin production and stimulation of the ...

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the ...

The DOXA platform, featuring compounds AEX-41 and AEX-2, targets both orexin-1 and orexin-2 receptors and aims to surpass the efficacy of existing narcolepsy therapies. Preliminary results from ...

are designed to target both orexin-1 and orexin-2 receptors while concurrently inhibiting cathepsins. Cathepsins play significant roles in a variety of physiological processes and may offer a ...

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024. An imbalance in Orexin production and stimulation of the ...